miR-126 reduces trastuzumab resistance by targeting PIK3R2 and regulating AKT/mTOR pathway in breast cancer cells

被引:37
作者
Fu Rao [1 ]
Tong Jing-Shan [2 ]
机构
[1] Northeast Elect Power Univ, Coll Chem Engn, Jilin, Jilin, Peoples R China
[2] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA
关键词
breast cancer; miR-126; PI3K; AKT; mTOR; trastuzumab resistance; HER2 SIGNALING PATHWAY; MOLECULAR-MECHANISMS; MUTATIONS; SUBUNIT;
D O I
10.1111/jcmm.15396
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
MicroRNAs (miRNAs) have been found to play a key role in drug resistance. In the current study, we aimed to explore the potential role of miR-126 in trastuzumab resistance in breast cancer cells. We found that the trastuzumab-resistant cell lines SKBR3/TR and BT474/TR had low expression of miR-126 and increased ability to migrate and invade. The resistance, invasion and mobilization abilities of the cells resistant to trastuzumab were reduced by ectopic expression of miR-126 mimics. In comparison, inhibition of miR-126 in SKBR3 parental cells had the opposite effect of an increased resistance to trastuzumab as well as invasion and migration. It was also found that miR-126 directly targets PIK3R2 in breast cancer cells. PIK3R2-knockdown cells showed decreased resistance to trastuzumab, while overexpression of PIK3R2 increased trastuzumab resistance. In addition, our finding showed that overexpression of miR-126 reduced resistance to trastuzumab in the trastuzumab-resistant cells and that inhibition of the PIK3R2/PI3K/AKT/mTOR signalling pathway was involved in this effect. SKBR3/TR cells also showed increased sensitivity to trastuzumab mediated by miR-126 in vivo. In conclusion, the above findings demonstrated that overexpression of miR-126 or down-regulation of its target gene may be a potential approach to overcome trastuzumab resistance in breast cancer cells.
引用
收藏
页码:7600 / 7608
页数:9
相关论文
共 49 条
[1]   Proteins Involved in HER2 Signalling Pathway, Their Relations and Influence on Metastasis-Free Survival in HER2-Positive Breast Cancer Patients Treated with Trastuzumab in Adjuvant Setting [J].
Adamczyk, Agnieszka ;
Grela-Wojewoda, Aleksandra ;
Domagala-Haduch, Malgorzata ;
Ambicka, Aleksandra ;
Harazin-Lechowska, Agnieszka ;
Janecka, Anna ;
Cedrych, Ida ;
Majchrzyk, Kaja ;
Kruczak, Anna ;
Rys, Janusz ;
Niemiec, Joanna .
JOURNAL OF CANCER, 2017, 8 (01) :131-139
[2]  
Asif Hafiz Muhammad, 2016, Asian Pac J Cancer Prev, V17, P1609
[3]   Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors [J].
Baldassari, Federica ;
Zerbinati, Carlotta ;
Galasso, Marco ;
Corra, Fabio ;
Minotti, Linda ;
Agnoletto, Chiara ;
Previati, Maurizio ;
Croce, Carlo M. ;
Volinia, Stefano .
FRONTIERS IN GENETICS, 2018, 9
[4]   A historic and scientific review of breast cancer: The next global healthcare challenge [J].
Becker, Sven .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2015, 131 :S36-S39
[5]  
Buzatto IPC, 2017, BRAZ J MED BIOL RES, V50, DOI [10.1590/1414-431x20165674, 10.1590/1414-431X20165674]
[6]  
Cai Yimei, 2009, Genomics Proteomics & Bioinformatics, V7, P147, DOI 10.1016/S1672-0229(08)60044-3
[7]   Involvement of miR-126 in autoimmune disorders [J].
Casciaro M. ;
Di Salvo E. ;
Brizzi T. ;
Rodolico C. ;
Gangemi S. .
Clinical and Molecular Allergy, 16 (1)
[8]   miRNA-126 enhances viability, colony formation, and migration of keratinocytes HaCaT cells by regulating PI3 K/AKT signaling pathway [J].
Chang, Lili ;
Liang, Jinning ;
Xia, Xiujuan ;
Chen, Xianjin .
CELL BIOLOGY INTERNATIONAL, 2019, 43 (02) :182-191
[9]  
Criscitiello C, 2013, FUTURE ONCOL, V9, P179, DOI [10.2217/fon.12.193, 10.2217/FON.12.193]
[10]   Glutathione S-transferase π: a potential role in antitumor therapy [J].
Dong, Shu-Chen ;
Sha, Huan-Huan ;
Xu, Xiao-Yue ;
Hu, Tian-Mu ;
Lou, Rui ;
Li, Huizi ;
Wu, Jian-Zhong ;
Dan, Chen ;
Feng, Jifeng .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 :3535-3547